_pmid,_doi,_publicationTitle,_year,_context,_confidence,_verdict,_usageType,assessmentName,assessmentType,targetPopulation,diseaseSpecific,numberOfItems,scoringMethod,validatedLanguages,psychometricProperties,administrationTime,availabilityStatus,licensingRequirements,digitalVersion
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,"...developmental delay assessed with the Survey of Well-being of Young Children...SWYC surveys conducted on the same days, which assess developmental milestones...",0.95,Accept,Experimental Usage,Survey of Well-being of Young Children (SWYC),questionnaire,pediatric,No,,,,,,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,...We used the LMS method from Centers for Disease Control (CDC) growth charts on head circumference to compute Z scores...,0.85,Accept,Experimental Usage,Centers for Disease Control (CDC) growth charts,scale,pediatric,No,,,,,,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,"Participants were children aged 12–17 years meeting the National Institute of Health (National Institutes of Health Consensus Development Conference, 1988) diagnostic criteria for NF1.",0.85,Accept,Experimental Usage,National Institute of Health diagnostic criteria for NF1,structured interview,all ages,Yes,,,,,,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,The aim of this study was to investigate P300 event-related potential (ERP) associated with WM in NF1...EEG was recorded during a WM nback task.,0.8,Accept,Experimental Usage,P300 event-related potential,biomarker assay,pediatric,No,,,,,,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,EEG was recorded during a WM nback task. The NF1 group showed poorer performance on measures of WM as compared to the control group.,0.75,Accept,Experimental Usage,WM nback task,performance test,pediatric,No,,,,,,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,"cNFs were laser-porated using the P.L.E.A.S.E.® device with the following user-defined settings: density of 10%, 5 pulses per pore, repetition rate of 300 Hz",0.85,Accept,Experimental Usage,P.L.E.A.S.E.® device,other,adult,Yes,,,,,,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,"visual and dermatoscopy observations (using the Dermlite DL3 [3Gen, San Jan Capistrano, CA, USA]) noting color and presence of necrosis",0.8,Accept,Experimental Usage,Dermlite DL3,other,adult,Yes,,,,,,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,"patients with a clinical diagnosis of NF1 according to the NIH Consensus Development Conference NF1 diagnostic criteria (NIH, 1998)",0.9,Accept,Experimental Usage,NIH Consensus Development Conference NF1 diagnostic criteria,structured interview,all ages,Yes,,,,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,The Numerical Rating Scale-11 is a self-report measure of pain intensity that was adapted to assess PN-related pain for NF1 clinical trials. Patients were asked to choose their most important tumor pain and rate it from 0 (no pain) to 10 (worst pain) in the past week.,0.9,Accept,Experimental Usage,Numerical Rating Scale-11,scale,all ages,Yes,1.0,0-10 scale,,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,The Brief Pain Inventory Pain Interference subscale assesses the impact of pain on daily functioning in seven areas from 0 (does not interfere) to 10 (completely interfered) in the past week; it yields a mean total score.,0.9,Accept,Experimental Usage,Brief Pain Inventory Pain Interference subscale,scale,all ages,No,7.0,"0-10 scale, mean total score",,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,The Pediatric Quality of Life Inventory NF1 module is a disease-specific health-related quality-of-life (QOL) measure assessing 16 domains. Responses on a five-point Likert scale are transformed to a scale of 0-100 (higher scores = better QOL); it produces mean domain and total scores.,0.95,Accept,Experimental Usage,Pediatric Quality of Life Inventory NF1 module,questionnaire,pediatric,Yes,16.0,"Likert 1-5, transformed to 0-100 scale",,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,"The cNF-Skindex is an 18-item questionnaire, including three domains: 'functioning', 'emotions', and 'symptoms'. Each item is scored on a 7-point Likert scale",0.95,Accept,Experimental Usage,cNF-Skindex,questionnaire,adult,Yes,18.0,"7-point Likert scale (0-6), total score 0-108",,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,"The EQ-5D-5L is a brief and generic health status measure that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression",0.9,Accept,Experimental Usage,EQ-5D-5L,questionnaire,adult,No,5.0,"5-level Likert responses, VAS 0-100",,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,"The 36-item Short Form Survey (SF-36) is a generic health-related QoL measure. It comprises eight domains of health: physical function, limitations because of physical problems",0.9,Accept,Experimental Usage,SF-36,questionnaire,adult,No,36.0,"0-100 scale, higher scores indicate better health",,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,The 2 primary outcomes were the physical health and psychological QOL domain scores of the World Health Organization Quality of Life Brief Version (WHOQOL-BREF),0.95,Accept,Experimental Usage,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),questionnaire,adult,No,26.0,0-100 transformed domain scores,,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,Perceived Stress Scale score of 6 or higher,0.9,Accept,Experimental Usage,Perceived Stress Scale,scale,adult,No,,,,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,"mind-body skills training program, the Relaxation Response Resiliency Program for NF (3RP-NF)",0.85,Accept,Experimental Usage,Relaxation Response Resiliency Program for NF (3RP-NF),structured interview,adult,Yes,,,,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,health education program (Health Enhancement Program for NF; HEP-NF),0.85,Accept,Experimental Usage,Health Enhancement Program for NF (HEP-NF),structured interview,adult,Yes,,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,We measure hearing function by DPOAE and ABR tests,0.85,Accept,Experimental Usage,DPOAE,performance test,all ages,No,,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,We measure hearing function by DPOAE and ABR tests,0.85,Accept,Experimental Usage,ABR,performance test,all ages,No,,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests",0.8,Accept,Experimental Usage,hind-limb clasping test,performance test,all ages,No,,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"In the CPA model, we found that the ledge test, which evaluates coordination, is the most sensitive test",0.8,Accept,Experimental Usage,ledge test,performance test,all ages,No,,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests",0.8,Accept,Experimental Usage,gait test,performance test,all ages,No,,,,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"Balance, motor strength, and coordination can be assayed by rotarod assay",0.8,Accept,Experimental Usage,rotarod assay,performance test,all ages,No,,,,,,,,
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,"measurements were performed at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, using a portable DG-HFUS device (Dermus SkinScanner, Dermus Ltd., Budapest, Hungary)",0.85,Accept,Experimental Usage,Dermus SkinScanner,biomarker assay,all ages,Yes,,,,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,"The MIA ELISA kit was purchased from (Roche Diagnostics, Indianapolis, IN, USA) and the measurements were conducted",0.85,Accept,Experimental Usage,MIA ELISA kit,biomarker assay,all ages,Yes,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"Full‐Scale IQ of at least 70, as determined by the Wechsler Abbreviated Scale of Intelligence (WASI 15 )",0.9,Accept,Experimental Usage,Wechsler Abbreviated Scale of Intelligence (WASI),performance test,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"the Brief Visuospatial Memory Test – Revised (BVMT, Immediate and Delayed 19 ; nonverbal declarative memory)",0.9,Accept,Experimental Usage,Brief Visuospatial Memory Test – Revised (BVMT),performance test,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,the Letter‐Number Sequencing task (LNS 20 ; working memory),0.9,Accept,Experimental Usage,Letter‐Number Sequencing task (LNS),performance test,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Digit Cancellation (attention/inhibitory control) 21,0.85,Accept,Experimental Usage,Digit Cancellation,performance test,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Hopkins Verbal Learning Test (HVLT; verbal declarative memory 22 ),0.9,Accept,Experimental Usage,Hopkins Verbal Learning Test (HVLT),performance test,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,WISC‐III Object Assembly (visuoconstructive ability) 23,0.9,Accept,Experimental Usage,WISC‐III Object Assembly,performance test,pediatric,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Achenbach Child Behavior Checklist (CBCL; self‐ and parent‐report),0.9,Accept,Experimental Usage,Achenbach Child Behavior Checklist (CBCL),questionnaire,pediatric,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"Young Adult Self Report (YASR) 24 ,  25",0.9,Accept,Experimental Usage,Young Adult Self Report (YASR),questionnaire,adult,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,the Neuropsychological Assessment Battery (NAB) Mazes 26,0.85,Accept,Experimental Usage,Neuropsychological Assessment Battery (NAB) Mazes,performance test,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency (category and letter fluency) 27,0.9,Accept,Experimental Usage,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,performance test,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Behavior Rating Inventory of Executive Function (BRIEF; General Executive Composite (GEC) score) 28,0.9,Accept,Experimental Usage,Behavior Rating Inventory of Executive Function (BRIEF),questionnaire,all ages,No,,,,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"A spatial working memory functional MRI paradigm, designed to be analogous to the behavioral tasks used in the mouse model",0.85,Accept,Experimental Usage,Spatial capacity working memory (SCAP) task,performance test,all ages,No,,,,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,Tumor size was classified by the Hannover and Koos classification systems,0.85,Accept,Experimental Usage,Hannover classification system,scale,all ages,Yes,,,,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,Tumor size was classified by the Hannover and Koos classification systems,0.85,Accept,Experimental Usage,Koos classification system,scale,all ages,Yes,,,,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,"the maximum linear (tumor) diameter (MLD) in axial and coronal (medial to lateral and caudal to rostral/cranial, in total four measurements per MRI) planes were measured according to the RECIST guidelines",0.8,Accept,Experimental Usage,RECIST guidelines,scale,all ages,No,,,,,,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,The Tinnitus Functional Index was identified as the most highly rated measure for the assessment of tinnitus in populations with neurofibromatosis type 2,0.95,Accept,Experimental Usage,Tinnitus Functional Index,questionnaire,adult,No,,,,,,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,The remaining 16 PROMs were submitted to a formal group review process using the Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE) form,0.9,Accept,Experimental Usage,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),scale,clinician-rated,No,,,,,,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,One measure was excluded (i.e. the Client Oriented Scale of Improvement-Tinnitus) because while it would be very useful for clinical settings,0.85,Accept,Citation Only,Client Oriented Scale of Improvement-Tinnitus,scale,adult,Yes,,,,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,Emotional and behavioral problems were measured using the Brief Symptom Inventory 18 (BSI-18) for adult respondents,0.9,Accept,Experimental Usage,Brief Symptom Inventory 18 (BSI-18),questionnaire,adult,No,18.0,,,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,Emotional and behavioral problems were measured using...the Behavior Problem Index (BPI) for adolescents (<18 years of age),0.9,Accept,Experimental Usage,Behavior Problem Index (BPI),questionnaire,pediatric,No,,,,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,"Neurocognitive outcomes were assessed for adult respondents with the CCSS Neurocognitive Questionnaire, which includes subscales measuring task efficiency, emotional regulation, organization, and memory",0.9,Accept,Experimental Usage,CCSS Neurocognitive Questionnaire,questionnaire,adult,No,,,,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,"Chronic health conditions were classified and severity-graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",0.9,Accept,Experimental Usage,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",scale,all ages,No,,,,,,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,The survey link was distributed via email to 1160 adolescent caregivers in the Children's Tumor Foundation NF Registry,0.85,Accept,Experimental Usage,Children's Tumor Foundation NF Registry,other,all ages,Yes,,,,,,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,Survey questions used 5-point Likert-type scales to measure ordered scale responses,0.8,Accept,Experimental Usage,5-point Likert-type scales,scale,pediatric,Yes,,Likert 1-5,,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The PEERS® intervention was administered by certified PEERS® providers...according to the PEERS® manual and the CARD telehealth manual,0.95,Accept,Experimental Usage,PEERS® intervention,structured interview,pediatric,No,14.0,14-week intervention program,,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The KBIT-2 is a brief measure of cognitive abilities including verbal reasoning and nonverbal reasoning...administered at the adolescent intake appointment,0.9,Accept,Experimental Usage,Kaufman Brief Intelligence Test– Second Edition (KBIT-2),performance test,pediatric,No,,"standard scores (M = 100, SD = 15)",,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The WIAT-III Word Reading subtest examines the ability to accurately read words...administered at the adolescent intake appointment,0.9,Accept,Experimental Usage,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,performance test,pediatric,No,,"standard score (M = 100, SD = 15)",,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The KSADS is a semi-structured caregiver interview to assess psychopathology...administered at the pre-test appointment to a caregiver,0.9,Accept,Experimental Usage,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),structured interview,caregiver,No,,4-point scale,,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The SCQ is a caregiver-report questionnaire that examines ASD symptomatology...has 40 items that are rated as 'Yes' or 'No',0.9,Accept,Experimental Usage,Social Communication Questionnaire (SCQ),questionnaire,caregiver,No,40.0,"Yes/No responses, raw score",,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The SSIS-SEL is a caregiver and self-report questionnaire measure examining social-emotional skills...Parent (51 items) and Student (46 items) forms,0.95,Accept,Experimental Usage,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),questionnaire,all ages,No,51.0,"4-point scale, standard score (M = 100, SD = 15)",,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The SRS-2 is a caregiver-report questionnaire of social impairment...includes 65 items that are rated on a 4-point scale,0.9,Accept,Experimental Usage,Social Responsiveness Scale– Second Edition (SRS-2),questionnaire,caregiver,No,65.0,"4-point scale, T-score (M = 50, SD = 10)",,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The FQS is a self-report questionnaire examining the friendship qualities...rate 23 items using a 5-point scale,0.9,Accept,Experimental Usage,Friendship Qualities Scale (FQS),questionnaire,pediatric,No,23.0,"5-point scale, total score 0-115",,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The QSQ is a caregiver and self-report questionnaire to gather information about the adolescent's get-togethers with peers,0.9,Accept,Experimental Usage,Quality of Socialization Questionnaire (QSQ),questionnaire,all ages,No,,raw scores on social initiation and reciprocity items,,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,The TASSK is a self-report 30-item questionnaire that measures knowledge of specific social skills taught as part of the PEERS® intervention,0.9,Accept,Experimental Usage,Test of Adolescent Social Skills Knowledge (TASSK),questionnaire,pediatric,No,30.0,"raw score, higher scores represent greater knowledge",,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,The original PII measure is a six-item self-report questionnaire that assesses pain interference using the past 2 weeks as a recall period,0.95,Accept,Development,Pain Interference Index (PII),questionnaire,pediatric,No,6.0,"0-6 scale, mean of six items",,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,"The six-item PII-P is formatted and scored in the same manner as the self-report PII, with total scores ranging from 0 to 6",0.95,Accept,Development,Pain Interference Index-Parent report (PII-P),questionnaire,caregiver,No,6.0,"0-6 scale, mean of six items",,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,"The MBPI, adapted from the adult Brief Pain Inventory, is a 12-item self-report questionnaire that measures pain interference",0.9,Accept,Experimental Usage,Modified Brief Pain Inventory (MBPI),questionnaire,pediatric,No,12.0,"0-10 scale, mean of all items",,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,The FPS-R is a one-item tool designed to provide an overall indicator of pain intensity at the time of the assessment,0.9,Accept,Experimental Usage,Faces Pain Scale-Revised (FPS-R),scale,pediatric,No,1.0,"0, 2, 4, 6, 8, or 10 points",,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,The PRS is a two-item visual analogue scale (VAS) developed by the authors that assesses pain intensity,0.85,Accept,Experimental Usage,Pain Rating Scale (PRS),scale,pediatric,No,2.0,100-mm visual analogue scale,,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,The Pain Rating Scale-Parent version (PRS-P) is similar to the VAS self-report PRS in terms of item content and format,0.85,Accept,Experimental Usage,Pain Rating Scale-Parent version (PRS-P),scale,caregiver,No,2.0,100-mm visual analogue scale,,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,"the NF Disease Severity Scale, adapted by our group from Ablon, asks the medical professional to rate the patient's symptoms as mild, moderate, or severe",0.8,Accept,Experimental Usage,NF Disease Severity Scale,scale,clinician-rated,Yes,,"mild, moderate, or severe rating",,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,"the NF1 Disease Complications Scale, is a checklist designed by a multi-disciplinary team of medical experts in NF1 at the National Institutes of Health",0.8,Accept,Experimental Usage,NF1 Disease Complications Scale,scale,clinician-rated,Yes,18.0,sum of endorsed diagnoses,,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,Hematoxylin and eosin (H&E)-stained tissue sections from each tumor were reviewed by a board-certified pathologist,0.85,Accept,Experimental Usage,Hematoxylin and eosin (H&E),biomarker assay,clinician-rated,No,,,,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,Patients from our institutional cohort with adequate tumor samples for immunohistochemical staining of DLK1,0.85,Accept,Experimental Usage,immunohistochemical staining,biomarker assay,clinician-rated,Yes,,,,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,Numerical Rating Scale-11 (NRS-11): The NRS-11 is a self-report 11-point numeric scale that assesses pain intensity,0.9,Accept,Experimental Usage,NRS-11,scale,all ages,No,11.0,0-10 scale,,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,Brief Pain Inventory (BPI)-Pain Interference (PI) Scale: The BPI-PI Scale is a 7-item self-report questionnaire that measures the extent to which pain interferes with daily functioning,0.9,Accept,Experimental Usage,BPI-PI Scale,questionnaire,all ages,No,7.0,"0-10 scale, mean of all 7 items",,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,PedsQL™ NF1 Module: This scale is a self-report measure assessing NF1 disease-specific QOL. Participants who were ages 21 years and older completed the 74-item self-report adult questionnaire,0.95,Accept,Experimental Usage,PedsQL NF1 Module,questionnaire,all ages,Yes,74.0,5-point Likert scale (0-4) transformed to 0-100 scale,,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"Levels of circulating sAXL were measured in human plasma using the Human AXL DuoSet ELISA kit (R&D Systems, DY154)",0.85,Accept,Experimental Usage,"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",biomarker assay,all ages,No,,,,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"Levels of circulating sAXL were measured in mouse plasma using the Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",0.85,Accept,Experimental Usage,"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",biomarker assay,all ages,No,,,,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,The FragEL™ DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21) was used according to manufacturer's instructions,0.8,Accept,Experimental Usage,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),biomarker assay,all ages,No,,,,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"Caspase 3/7 Glo activity (#G8093, Promega) was measured by luminescence after 24 hours of treatment",0.8,Accept,Experimental Usage,"Caspase 3/7 Glo activity (#G8093, Promega)",biomarker assay,all ages,No,,,,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,radiographic tumor burden was quantified by sum of the longest tumor diameters (SLD) per RECIST 1.1 criteria,0.95,Accept,Experimental Usage,RECIST 1.1,scale,adult,No,,,,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,The 3-chamber SP task occurred over 2 days as described previously,0.85,Accept,Experimental Usage,3-chamber social preference task,performance test,all ages,No,,,,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"mice were placed in the dark in an open chamber (40 × 40 cm, 30 cm height) for 60 minutes while activity was recorded",0.85,Accept,Experimental Usage,Open field test,performance test,all ages,No,,,,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,mice were trained to identify which side of a T maze had a large reward (4 Cocoa Krispies) compared with the small reward (1 Cocoa Krispie),0.85,Accept,Experimental Usage,Delay discounting task,performance test,all ages,No,,,,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"a round, plastic platform (diameter, 20 cm; thickness, 2 cm) supported by a plastic rod (height, 50 cm) was used to assess the CAR",0.85,Accept,Experimental Usage,Cliff avoidance reaction test,performance test,all ages,No,,,,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"The objective of this study was to develop an NF1 HRQOL instrument as a module of PedsQL™ and to test for its initial feasibility, internal consistency reliability and validity in adults with NF1.",0.95,Accept,Development,PedsQL™ NF1 Module,questionnaire,adult,Yes,74.0,0-100 scale,,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"The NF1 HRQOL format, instructions, and Likert response scale are similar to the PedsQL™ 4.0 Generic Core Scales and other PedsQL™ Disease-Specific Modules.",0.85,Accept,Citation Only,PedsQL™ 4.0 Generic Core Scales,scale,all ages,No,,0-100 scale,,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Citation Only,PedsQL™ Arthritis Module,questionnaire,all ages,Yes,,,,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Citation Only,PedsQL™ Cancer Module,questionnaire,all ages,Yes,,,,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Citation Only,PedsQL™ Cerebral Palsy Module,questionnaire,all ages,Yes,,,,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Citation Only,PedsQL™ Family Impact Module,questionnaire,caregiver,No,,,,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,"Participants completed the Life Events Checklist, adapted from Elliott-DeSorbo et al. [ 30 ], to document stressful events in the past three months. The score is the number of stressful events endorsed (range 0–22).",0.85,Accept,Experimental Usage,Life Events Checklist (LEC),questionnaire,adult,No,22.0,sum score,,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,Participants rated their stress in the past month from 0 (not stressed) to 10 (very stressed). This measure was adapted from Leidy et al. [ 31 ].,0.85,Accept,Experimental Usage,Rating of Overall Stress Scale (ROSS),scale,adult,No,,0–10 scale,,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].",0.9,Accept,Experimental Usage,PROMIS depression short form,questionnaire,adult,No,8.0,"T-scores (M = 50, SD = 10)",,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].",0.9,Accept,Experimental Usage,PROMIS pain interference short form,questionnaire,adult,No,6.0,"T-scores (M = 50, SD = 10)",,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].",0.9,Accept,Experimental Usage,PROMIS cognitive function short form,questionnaire,adult,No,8.0,"T-scores (M = 50, SD = 10)",,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,"Participants' study drug bottles were fitted with a MEMS TM cap at baseline. Having been given instructions to take the drug 12 h apart, adherence was defined as opening the bottle 11–13 h since their last dose.",0.85,Accept,Experimental Usage,MEMS Cap,performance test,adult,No,,,,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,The barriers to adherence measure was created by the study team; participants were asked to think of times they missed a dose of their study drug in the past month and marked which of 16 possible reasons caused them to miss a dose.,0.8,Accept,Experimental Usage,Barriers to Adherence Questionnaire,questionnaire,adult,Yes,16.0,,,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,"The Impact of NF1 on Quality of Life (INF1-QOL) questionnaire was developed by a literature search for common terms, focus group (n = 6), semi-structured interviews (n = 21)",0.95,Accept,Development,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,questionnaire,adult,Yes,14.0,"0-3 scale per item, maximum score 42",,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,"The EuroQol (EQ 5D) contains a global health score and covers Mobility, Self-care, Usual Activities, Pain/Discomfort, Anxiety and Depression",0.9,Accept,Experimental Usage,EuroQol (EQ 5D),questionnaire,adult,No,5.0,global health score,,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Disease severity was determined using the Riccardi NF severity grade classification 1 to 4. Grades 1 and 2 were amalgamated to ensure adequate numbers in each group,0.85,Accept,Experimental Usage,Riccardi NF severity grade classification,scale,adult,Yes,4.0,1-4 grade classification,,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Adults (18 years or older) who fulfilled the diagnostic criteria for NF1 (NIH Consensus Development Conference 1987) and attended the National NF1 service,0.8,Accept,Experimental Usage,NIH Consensus Development Conference 1987 diagnostic criteria,structured interview,all ages,Yes,,,,,,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,"...response of three or higher on a pain interference item (1–5 scales) from a self-report or parent-report QOL measure (Impact of Pediatric Illness Scale [ Wolters et al., 2010 ])",0.85,Accept,Experimental Usage,Impact of Pediatric Illness Scale,scale,pediatric,No,,1–5 scale,,,,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,...two scales developed by the authors for the current study assessed pain management techniques used by the patients (Pain Management Inventory),0.8,Accept,Development,Pain Management Inventory,scale,pediatric,Yes,,,,,,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,...treatment adherence and study satisfaction (Post-Treatment Questionnaire). Details on these measures are in Table I,0.8,Accept,Development,Post-Treatment Questionnaire,questionnaire,pediatric,Yes,,,,,,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,The inclusion criteria for the pain group were an average pain score of ≥ 3 on the visual analogue 0–10 scale over the previous 10 weeks,0.9,Accept,Experimental Usage,visual analogue scale,scale,adult,No,,0-10 scale,,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,AtDCS was delivered via a NeuroConn DC-STIMULATOR MR with the anode placed over F3 position in the international 10–20 system,0.85,Accept,Experimental Usage,NeuroConn DC-STIMULATOR MR,performance test,pediatric,No,,,,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,Parent-rated Vineland Adaptive Behaviour Scale—third edition was administered to the parents to assess child adaptive behaviour,0.95,Accept,Experimental Usage,Vineland Adaptive Behaviour Scale—third edition,scale,caregiver,No,,,,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,Conners 3 rating scale was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale,0.95,Accept,Experimental Usage,Conners 3 rating scale,scale,caregiver,No,27.0,Likert 0-3,,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,"All participants completed the age-appropriate digit-span subtest of the Wechsler Adult and Children Intelligence Scales (Wechsler, 2002, 2004)",0.9,Accept,Experimental Usage,Wechsler Adult and Children Intelligence Scales,performance test,all ages,No,,,,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,"All participants completed...the Corsi block-tapping task (Kessels et al., 2000, 2008). Both are span tasks where the examiner presents a growing sequence",0.85,Accept,Experimental Usage,Corsi block-tapping task,performance test,all ages,No,,,,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III for adults and children,0.9,Accept,Experimental Usage,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),performance test,all ages,No,,,,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,"We adopted the arithmetic subtest from the School Achievement Test (Stein, 1994), as an objective measure of school performance",0.85,Accept,Experimental Usage,School Achievement Test,performance test,pediatric,No,,,,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,Socioeconomic status (SES) was assessed using the Brazilian Criterion for Economic Classification (CCEB) according to the criteria established,0.8,Accept,Experimental Usage,Brazilian Criterion for Economic Classification (CCEB),questionnaire,adult,No,10.0,0-46 points scale,,,,,,
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,"the meningioma recurrence score (MRS) generated by our machine learning algorithm revealed multiple predictive factors of recurrence, including age, female gender, and various histopathologic features, including the Ki-67/MIB-1 index.",0.75,Accept,Experimental Usage,Ki-67/MIB-1 index,biomarker assay,adult,No,,,,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,Rey complex figure test (CFT) (delayed recall; assessing nonverbal long-term memory),0.9,Accept,Experimental Usage,Rey complex figure test,performance test,pediatric,No,,,,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,performance on the cancellation test (speed; assessing attention),0.85,Accept,Experimental Usage,cancellation test,performance test,pediatric,No,,,,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,performance on a prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion),0.8,Accept,Experimental Usage,prism adaptation task,performance test,pediatric,No,,,,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,the Stroop color word test,0.9,Accept,Experimental Usage,Stroop color word test,performance test,pediatric,No,,,,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,"assessed at baseline using the Wechsler Intelligence Scale for Children–Revised, Dutch version",0.95,Accept,Experimental Usage,Wechsler Intelligence Scale for Children–Revised,scale,pediatric,No,,,,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,the Beery developmental test of visual-motor integration,0.9,Accept,Experimental Usage,Beery developmental test of visual-motor integration,performance test,pediatric,No,,,,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,and the judgment of line orientation task,0.85,Accept,Experimental Usage,judgment of line orientation task,performance test,pediatric,No,,,,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,"Optical coherence tomography images were obtained using Cirrus HD-OCT device (Cirrus; Carl Zeiss Meditec, Dublin, CA, USA)",0.9,Accept,Experimental Usage,Cirrus HD-OCT,biomarker assay,pediatric,Yes,,,,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,In the youngest group VA was assessed with Teller acuity cards or Cardiff acuity cards,0.85,Accept,Experimental Usage,Teller acuity cards,performance test,pediatric,No,,,,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,In the youngest group VA was assessed with Teller acuity cards or Cardiff acuity cards,0.85,Accept,Experimental Usage,Cardiff acuity cards,performance test,pediatric,No,,,,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,while older children were tested with Lea or KM (Konstantin Moutakis) cards,0.85,Accept,Experimental Usage,Lea cards,performance test,pediatric,No,,,,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,while older children were tested with Lea or KM (Konstantin Moutakis) cards,0.85,Accept,Experimental Usage,KM (Konstantin Moutakis) cards,performance test,pediatric,No,,,,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Visual fields were assessed with the Humphrey Field Analyzer perimetry as previously described,0.9,Accept,Experimental Usage,Humphrey Field Analyzer perimetry,performance test,pediatric,No,,,,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,In children ≥4 years of age VA at initial visit was compared with World Health Organization Categories of Childhood VI scale for reference,0.9,Accept,Experimental Usage,World Health Organization Categories of Childhood VI scale,scale,pediatric,No,,,,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,Children rated tumor pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable)...pain intensity (11-point Numerical Rating Scale [NRS-11]),0.95,Accept,Experimental Usage,Numerical Rating Scale (NRS-11),scale,pediatric,No,11.0,0-10 scale,,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,"interference of pain in daily functioning (Pain Interference Index)...Scores on the Pain Interference Index range from 0 to 6, with higher scores indicating greater pain interference",0.9,Accept,Experimental Usage,Pain Interference Index,scale,pediatric,No,,0-6 scale,,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,"health-related quality of life (Pediatric Quality of Life Inventory [PedsQL] Generic Core Scales)...PedsQL scores range from 0 to 100, with higher scores indicating better health-related quality of life",0.95,Accept,Experimental Usage,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,questionnaire,pediatric,No,,0-100 scale,,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,perceived changes with treatment (Global Impression of Change scale)...Scores on the Global Impression of Change scale range from 1 (very much improved) to 7 (very much worse),0.9,Accept,Experimental Usage,Global Impression of Change scale,scale,pediatric,No,7.0,1-7 scale,,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning,0.95,Accept,Experimental Usage,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,questionnaire,pediatric,No,,"T scores with mean 50, SD 10",,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning,0.95,Accept,Experimental Usage,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,questionnaire,pediatric,No,,"T scores with mean 50, SD 10",,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,"Adverse events were graded with the use of the NCI Common Terminology Criteria for Adverse Events, version 4.0",0.95,Accept,Experimental Usage,"NCI Common Terminology Criteria for Adverse Events, version 4.0",scale,all ages,No,,,,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,Response to treatment was monitored by using volumetric magnetic resonance imaging analysis to measure the change in size of the plexiform neurofibroma,0.85,Accept,Experimental Usage,volumetric magnetic resonance imaging analysis,biomarker assay,pediatric,Yes,,,,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,Adherence to the dosing schedule was assessed by administration of the Responsibility for Medication Questionnaire,0.8,Accept,Experimental Usage,Responsibility for Medication Questionnaire,questionnaire,pediatric,No,,,,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,"Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",0.9,Accept,Experimental Usage,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",scale,all ages,No,,,,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria),0.85,Accept,Citation Only,Response Evaluation Criteria In Solid Tumors (RECIST),scale,all ages,No,,,,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria),0.85,Accept,Citation Only,World Health Organization (WHO) criteria,scale,all ages,No,,,,,,,,
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,A Likert scale questionnaire was used to survey clinicians' levels of agreement with 25 statements related to 2D and 3D tumor analyses.,0.85,Accept,Experimental Usage,Likert scale questionnaire,questionnaire,clinician-rated,Yes,25.0,Likert 1-5,,,,,,
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,Speech perception ability in background noise was evaluated in device-active and inactive conditions using the CNC-word test.,0.85,Accept,Experimental Usage,CNC-word test,performance test,pediatric,No,,,,,,,,
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,Listening and communication ratings (LIFE-R Questionnaire) were obtained at baseline and at the end of each treatment phase.,0.9,Accept,Experimental Usage,LIFE-R Questionnaire,questionnaire,pediatric,No,,,,,,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,One was the Rex Gauge durometer (REX) produced by Rex Gauge LLC...used to measure cNF stiffness,0.9,Accept,Experimental Usage,Rex Gauge durometer,performance test,all ages,Yes,,Shore Hardness Scale 0-100,,,,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,"the other was the SkinFibroMeter (DEFLIN) made by Delfin Technologies...measure tissue induration, assessing tissue stiffness in quantitative units",0.9,Accept,Experimental Usage,Delfin SkinFibroMeter,performance test,all ages,Yes,,force measurement in Newtons,,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Vectra H1 (Canfield Scientific Inc, Fairfield, NJ, USA)",0.9,Accept,Experimental Usage,Vectra H1,performance test,adult,Yes,,,,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: LifeViz Micro (QuantifiCare, Biot, France)",0.9,Accept,Experimental Usage,LifeViz Micro,performance test,adult,Yes,,,,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Cherry Imaging (Yokneam, Israel)",0.9,Accept,Experimental Usage,Cherry Imaging,performance test,adult,Yes,,,,,,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,"When significantly reduced, the compound motor action potential (CMAP) – correlating with the number of functional axons – is an indicator for axonal damage.",0.85,Accept,Experimental Usage,compound motor action potential (CMAP),biomarker assay,all ages,No,,,,,,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,"By measuring nerve properties as conduction velocity or potential amplitudes of the signal, it is possible to characterize the origin of peripheral nerve diseases.",0.8,Accept,Experimental Usage,nerve conduction velocity,performance test,all ages,No,,,,,,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,Electrophysiological measurements are an indispensable tool for investigating the functional integrity of peripheral nerves in both the clinical and laboratory environment.,0.75,Accept,Experimental Usage,electrophysiological measurements,performance test,all ages,No,,,,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,The water maze task was performed as previously described. Before performing the water maze task,0.9,Accept,Experimental Usage,Morris water maze,performance test,all ages,No,,,,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,"Motor learning was assessed with the accelerating rotarod (Ugo Basile, Comerio Varese, Italy)",0.9,Accept,Experimental Usage,Rotarod,performance test,all ages,No,,,,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,"We recorded EEG data with an EGI (Philips Neuro, Oregon, USA) 128-electrode Hydrocel Sensor Net, with the vertex electrode...",0.85,Accept,Experimental Usage,EGI 128-electrode Hydrocel Sensor Net,biomarker assay,pediatric,No,,,,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,The Mullen Scales of Early Learning (MSEL) is a standardised measure that assesses developmental ability across five domains...,0.95,Accept,Experimental Usage,Mullen Scales of Early Learning (MSEL),scale,pediatric,No,,raw scores for subdomains,,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,The Autism Observation Score for Infants (AOSI) is a standardised research assessment that examines ASD traits in infants...,0.95,Accept,Experimental Usage,Autism Observation Score for Infants (AOSI),structured interview,pediatric,Yes,,,,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,The IBQ-R is a parent-report questionnaire consisting of 191 items and 14 scales that relate to different aspects of infant temperament...,0.9,Accept,Experimental Usage,Infant Behaviour Questionnaire-Revised (IBQ-R),questionnaire,caregiver,No,191.0,7-point Likert scale,,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,Parents completed the MacArthur Bates Communicative Development Inventory (CDI) long form measures early language abilities...,0.9,Accept,Experimental Usage,MacArthur Bates Communicative Development Inventory (CDI),questionnaire,caregiver,No,800.0,1–3-point scale,,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,All participants had their diagnosis confirmed via molecular testing of cord blood samples or clinical diagnosis based on NIH consensus criteria,0.85,Accept,Experimental Usage,NIH consensus criteria,structured interview,all ages,Yes,,,,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,"a strong positive COVID-19 diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10)",0.9,Accept,Experimental Usage,"International Classification of Diseases, 10th Revision (ICD-10)",scale,all ages,No,,,,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,"diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10) or Systematized Nomenclature of Medicine (SNOMED) tables",0.9,Accept,Experimental Usage,Systematized Nomenclature of Medicine (SNOMED),scale,all ages,No,,,,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon",0.85,Accept,Experimental Usage,Logical Observation Identifiers Names and Codes (LOINC),scale,all ages,No,,,,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon",0.8,Accept,Experimental Usage,Nebraska Lexicon,scale,all ages,No,,,,,,,,
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,,The disease-focused NF2 impact on quality of life (NFTI-QOL) patient questionnaire was assessed as an outcome measure for treatment in a multi-centre study.,0.95,Accept,Experimental Usage,NFTI-QOL,questionnaire,adult,Yes,8.0,"four-point scale, range 0–3, with three as the most impaired, total score of 24",,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"Mouse cytokine protein expressions were quantified using mouse cytokine array (panel A, R&D system, Minneapolis, MN)",0.8,Accept,Experimental Usage,"mouse cytokine array (panel A, R&D system)",biomarker assay,all ages,No,,,,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,"...ages ≤ 25 years with a diagnosis of NF1, as defined by the NIH Consensus Conference criteria [19]...",0.85,Accept,Experimental Usage,NIH Consensus Conference criteria,scale,all ages,Yes,,,,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...,0.9,Accept,Experimental Usage,Lansky performance status,scale,pediatric,No,,0-100 scale,,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...,0.9,Accept,Experimental Usage,Karnofsky performance status,scale,adult,No,,0-100 scale,,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,...Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0...,0.95,Accept,Experimental Usage,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,scale,all ages,No,,,,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,...Analysis of functional responses for the cohort of participants with airway involvement were guided by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) sleep and pulmonary outcomes recommendations...,0.95,Accept,Experimental Usage,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),scale,all ages,Yes,,,,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,"This study sought to develop a self-administered questionnaire in French to assess the burden of NF1 (BoN), then translate and linguistically and cross-culturally validate it",0.95,Accept,Development,BoN (Burden of NF1) questionnaire,questionnaire,adult,Yes,15.0,"6-point Likert scale: never (0), rarely (1), sometimes (2), often (3), very often (4), constantly (5)",,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,all participants were asked to complete three previously validated self-administered questionnaires: the Dermatology Life Quality Index [DLQI] questionnaire,0.9,Accept,Experimental Usage,Dermatology Life Quality Index (DLQI),questionnaire,adult,No,,"0–30 scale, with high scores reflecting poor QoL",,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,The PSS is the most widely used psychological instrument for measuring the perception of stress. Composed of 10 items rated from never to often,0.9,Accept,Experimental Usage,Perceived Stress Scale (PSS),scale,adult,No,10.0,"10 to 50 scale, higher score indicates higher stress",,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,"The SF12 is a short version of the SF-36, namely a generic instrument to measure population health with a physical composite score and mental composite score calculated based on 12 questions",0.9,Accept,Experimental Usage,SF12,questionnaire,adult,No,12.0,"composite scores, higher score indicates better physical and mental quality of life",,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,meeting ASD cut-off on the Autism Diagnostic Interview Revised (ADI-R)...Autism Diagnostic Interview-Revised (ADI-R) was used for detailed parent interviews,0.95,Accept,Experimental Usage,Autism Diagnostic Interview Revised (ADI-R),structured interview,pediatric,No,87.0,0-3 scale,,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,scoring above the ASD cut-off on the Autism Diagnostic Observation Schedule-2 (ADOS-2)...The Autism Diagnostic Observation Schedule–second edition (ADOS-2) was used to measure current autism clinical profile,0.95,Accept,Experimental Usage,Autism Diagnostic Observation Schedule-2 (ADOS-2),structured interview,pediatric,No,4.0,0-3 scale,,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,"The Wechsler Abbreviated Scale of Intelligence-II (WASI-II) was used to measure verbal intellectual functioning (VIQ), based on two subscales called Similarities and Vocabulary",0.9,Accept,Experimental Usage,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),performance test,pediatric,No,,,,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,"Conners Parent Rating Scale (3rd edition, short form) measured ADHD symptomatology. The two domains, inattention and hyperactivity, were used in the study and presented in T-score",0.9,Accept,Experimental Usage,"Conners Parent Rating Scale (3rd edition, short form)",scale,caregiver,No,,T-score,,,,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,"All MRI sequences were performed on a 1.5 T scanner (Magnetom Avanto, Siemens Healthineers, Erlangen, Germany)",0.85,Accept,Experimental Usage,Magnetom Avanto,biomarker assay,all ages,Yes,,,,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"Full-Scale IQ ≥ 70 (as determined by the Wechsler Abbreviated Scale of Intelligence [WASI]; Wechsler, 2011)",0.9,Accept,Experimental Usage,Wechsler Abbreviated Scale of Intelligence (WASI),scale,adult,No,,,,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"same measures from the Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV; Wechsler, 2014) for the healthy controls",0.9,Accept,Experimental Usage,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",scale,adult,No,,,,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"Working memory capacity was measured behaviorally using the University of Maryland Letter–Number Sequencing (LNS) task (Gold et al., 1997)",0.85,Accept,Experimental Usage,University of Maryland Letter–Number Sequencing (LNS) task,performance test,adult,No,,,,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"Participants viewed a visual array presenting 1, 3, 5, or 7 circles on the screen followed by a probe circle",0.9,Accept,Experimental Usage,Spatial capacity working memory (SCAP) task,performance test,adult,No,,,,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,parent-reported Adaptive Behaviour Composite (ABC) scores on the Vineland Adaptive Behaviour Scale (VABS-III),0.95,Accept,Experimental Usage,Vineland Adaptive Behaviour Scale (VABS-III),scale,caregiver,No,,,,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG",0.8,Accept,Experimental Usage,adaptive auditory n-back task,performance test,pediatric,No,,,,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG",0.8,Accept,Experimental Usage,non-adaptive visual n-back task,performance test,pediatric,No,,,,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,responses to the Brief Pain Inventory Short Form (BPI-SF) [ 8 ]...a pain severity aggregate score of ≥3 on the BPI-SF [ 8 ] for pain experienced in the previous 2 weeks,0.95,Accept,Experimental Usage,Brief Pain Inventory Short Form (BPI-SF),questionnaire,adult,No,,aggregate score,,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,responses to...Patient Health Questionnaire (PHQ) [ 19 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7,0.9,Accept,Experimental Usage,Patient Health Questionnaire (PHQ),questionnaire,adult,No,,,,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,Structured Clinical Interview for DSM Self Report version (SCID-SR) [ 20 ]...evidence of psychosis or schizophrenia on the SCID-SR [ 20 ],0.95,Accept,Experimental Usage,Structured Clinical Interview for DSM Self Report version (SCID-SR),structured interview,adult,No,,,,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,Generalized Anxiety Disorder 7 Item version (GAD-7) [ 21 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7,0.95,Accept,Experimental Usage,Generalized Anxiety Disorder 7 Item version (GAD-7),scale,adult,No,7.0,,,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,The PHQ-9 and GAD-7 are copyrighted by Pfizer Inc. and are freely available for research and clinical use,0.9,Accept,Experimental Usage,PHQ-9,questionnaire,adult,No,9.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Children with NF1 that screen at risk for ASD on the parent-rated Social Responsiveness Scale 2nd Edition will be invited back to complete...,0.95,Accept,Experimental Usage,Social Responsiveness Scale 2nd Edition,scale,caregiver,No,65.0,T-score ≥60 indicates at risk,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria,0.95,Accept,Experimental Usage,Autism Diagnostic Observation Scale 2nd Edition,structured interview,pediatric,Yes,,combined domain total of ≥7 for ASD criteria,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria,0.95,Accept,Experimental Usage,Autism Diagnostic Interview-Revised,structured interview,caregiver,Yes,95.0,algorithm scores for three domains,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,WPPSI-IV 10 subtests providing 5 indices and full scale IQ Y,0.9,Accept,Experimental Usage,WPPSI-IV,performance test,pediatric,No,,5 indices and full scale IQ,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,WISC-V 10 subtests providing 5 indices and full scale IQ S,0.9,Accept,Experimental Usage,WISC-V,performance test,pediatric,No,,5 indices and full scale IQ,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Sky Search Assessing the ability to selectively attend to and identify 20 visual targets among distractors S,0.85,Accept,Experimental Usage,TEA-Ch Sky Search,performance test,pediatric,No,,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Score! 10 trials assessing the ability to sustain attention by mentally counting aurally administered tones S,0.85,Accept,Experimental Usage,TEA-Ch Score!,performance test,pediatric,No,,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Shape School 4 conditions (each with 15 items) assessing inhibition, task-switching and working memory abilities",0.85,Accept,Experimental Usage,Shape School,performance test,pediatric,No,60.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NESPY-II Inhibition 6 items assessing the ability to inhibit automatic responses in favour of novel responses,0.85,Accept,Experimental Usage,NEPSY-II Inhibition,performance test,pediatric,No,6.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Tower of Hanoi 6 items assessing set shifting, response inhibition, working memory and the ability to hold a set of rules in mind",0.85,Accept,Experimental Usage,Tower of Hanoi,performance test,pediatric,No,6.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Creature Counting 7 trials assessing the ability to accurately switch and redirect attention to count up/down S,0.85,Accept,Experimental Usage,TEA-Ch Creature Counting,performance test,pediatric,No,,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"WIAT-II Abbreviated 3 subtests assessing numerical operations, spelling and single word reading S",0.85,Accept,Experimental Usage,WIAT-II Abbreviated,performance test,pediatric,No,,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II Affect Recognition 36 items assessing the ability to match facial expressions from photographs of children's faces,0.85,Accept,Experimental Usage,NEPSY-II Affect Recognition,performance test,pediatric,No,36.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Benton Facial Recognition Test 13 items assessing the ability to recognise a target face from a selection of distractors S,0.85,Accept,Experimental Usage,Benton Facial Recognition Test,performance test,pediatric,No,13.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"NEPSY-II ToM 21 items assessing the ability to comprehend the perspectives, intentions and beliefs of another person",0.85,Accept,Experimental Usage,NEPSY-II ToM,performance test,pediatric,No,21.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Reading the Mind in the Eyes Test-Child 28 items assessing the ability to determine a person's thoughts or feelings based on a picture of only their eyes,0.85,Accept,Experimental Usage,Reading the Mind in the Eyes Test-Child,performance test,pediatric,No,28.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Faux Pas Task 20 short stories assessing the ability to identify a social faux pas S,0.85,Accept,Experimental Usage,Faux Pas Task,performance test,pediatric,No,20.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Strange Stories 14 short stories assessing the ability to attribute mental states (eg, desires, beliefs or intentions)",0.85,Accept,Experimental Usage,Strange Stories,performance test,pediatric,No,14.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CELF-Preschool-2 2 subtests assessing knowledge of grammatical rules in a sentence completion task and the ability to name objects, people and activities Y",0.85,Accept,Experimental Usage,CELF-Preschool-2,performance test,pediatric,No,,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CELF-4 Formulated Sentences 28 items assessing the ability to formulate semantically and grammatically correct spoken sentences,0.85,Accept,Experimental Usage,CELF-4 Formulated Sentences,performance test,pediatric,No,28.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II Comprehension of Instructions 33 items assessing the ability to comprehend and follow multistep instructions of increasing complexity,0.85,Accept,Experimental Usage,NEPSY-II Comprehension of Instructions,performance test,pediatric,No,33.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"SRS-2 65 items assessing the presence and severity of ASD symptoms including social awareness, social cognition, social communication",0.9,Accept,Experimental Usage,SRS-2,scale,caregiver,Yes,65.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CADS 26 items assessing ADHD symptoms of impulsivity/hyperactivity and inattention Y,0.85,Accept,Experimental Usage,CADS,scale,caregiver,No,26.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Conners 3 110 items assessing ADHD symptom and comorbid disorders including oppositional defiant and conduct problems,0.85,Accept,Experimental Usage,Conners 3,scale,caregiver,No,110.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"BRIEF-Preschool 63 items assessing executive functions within the home environment, including working memory, mental set shifting",0.85,Accept,Experimental Usage,BRIEF-Preschool,scale,caregiver,No,63.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"BRIEF 86 items assessing executive functions in the home environment, including working memory, mental set shifting, response inhibition",0.85,Accept,Experimental Usage,BRIEF,scale,caregiver,No,86.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"ABAS-3: 0–5 years 241 items assessing adaptive functioning skills, including communication, community use, preacademics",0.85,Accept,Experimental Usage,ABAS-3: 0–5 years,scale,caregiver,No,241.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"ABAS-3: 5–21 years 232 items assessing adaptive functioning skills, including communication, community use, functional academics",0.85,Accept,Experimental Usage,ABAS-3: 5–21 years,scale,caregiver,No,232.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"SSIS Rating Scale 79 items assessing social skills, problem behaviours and academic competence Y, S",0.85,Accept,Experimental Usage,SSIS Rating Scale,scale,caregiver,No,79.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Sensory Profile 2 86 items assessing sensory processing, including auditory, visual, taste/smell, movement, body position, touch",0.85,Accept,Experimental Usage,Sensory Profile 2,scale,caregiver,No,86.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CBCL: 1.5–5 years 100 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression",0.85,Accept,Experimental Usage,CBCL: 1.5–5 years,scale,caregiver,No,100.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CBCL: 6–18 years 113 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression",0.85,Accept,Experimental Usage,CBCL: 6–18 years,scale,caregiver,No,113.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CCC-2 70 items assessing speech, syntax, semantics, coherence, inappropriate initiation, stereotyped language, use of context",0.85,Accept,Experimental Usage,CCC-2,scale,caregiver,No,70.0,,,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"acquire two GABA-edited magnetic resonance spectra using the localised spectroscopy sequence MEGA-PRESS, developed by CMRR",0.8,Accept,Experimental Usage,MEGA-PRESS,biomarker assay,pediatric,No,,,,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Verbal and visuospatial working memory was assessed using the n-back task. The task was programmed in-house using E-Prime software.,0.85,Accept,Experimental Usage,n-back task,performance test,pediatric,No,24.0,accuracy as proportion of correctly identified hits + correct omissions,,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Memory span was assessed using a computerized Corsi block task on the Psychology Experiment Building Language (PEBL),0.85,Accept,Experimental Usage,Corsi block task,performance test,pediatric,No,,memory span computed,,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Auditory working memory was assessed using the digit span forward and back task of the Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),0.9,Accept,Experimental Usage,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),performance test,pediatric,No,,,,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Parent-rated Vineland Adaptive Behavior Scale—third edition (Hill et al. 2017) was administered to the parents to assess child adaptive behavior,0.9,Accept,Experimental Usage,Vineland Adaptive Behavior Scale—third edition,scale,caregiver,No,,adaptive behavior composite (ABC),,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,Conners 3 rating scale(Conners et al. 2011) was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale,0.9,Accept,Experimental Usage,Conners 3 rating scale,scale,caregiver,No,27.0,Likert 1-4,,,,,,
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,The PlexiQoL questionnaire is a disease-specific QoL measure for adults with NF1-associated plexiform neurofibromas...consists of 18 items with a dichotomous response option,0.95,Accept,Experimental Usage,PlexiQoL,questionnaire,adult,Yes,18.0,sum score 0-18,,,,,,
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,The Nottingham Health Profile (NHP) questionnaire was used as comparator questionnaire to evaluate convergent validity...consists of 38 items that cover six subsections,0.9,Accept,Experimental Usage,Nottingham Health Profile (NHP),questionnaire,adult,No,38.0,0-100 scale per subsection,,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,Gross motor coordination function was evaluated using the Rotarod (Med Associates),0.85,Accept,Experimental Usage,Rotarod,performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),0.95,Accept,Experimental Usage,WAIS-III,performance test,adult,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),0.95,Accept,Experimental Usage,WISC-III,performance test,pediatric,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Nine-Hole Peg Test was performed as a measure of finger dexterity. It measures the time (in seconds) needed to complete the test,0.9,Accept,Experimental Usage,Nine-Hole Peg Test,performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Rey-Osterrieth Complex Figure Test was implemented as a measure of the visuospatial cognitive domain,0.9,Accept,Experimental Usage,Rey-Osterrieth Complex Figure Test,performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Immediate (A6) and delayed recalls (A7) of the Brazilian-Portuguese version of the Rey Auditory-Verbal Learning Test (RAVLT) were taken as measures of verbal episodic memory,0.9,Accept,Experimental Usage,Rey Auditory-Verbal Learning Test (RAVLT),performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"Assessment of this cognitive domain was performed by a Category Fluency Test (""animals"")",0.85,Accept,Experimental Usage,Category Fluency Test,performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"and by Lexical Fluency Test letters (F, A, and S)",0.85,Accept,Experimental Usage,Lexical Fluency Test,performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Five Digits Test (FDT) is a numeric-Stroop paradigm designed to assess attentional processes,0.9,Accept,Experimental Usage,Five Digits Test (FDT),performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"For working memory evaluation, we used the Digit Span according to the WAIS-III or WISC-III, and the Corsi block-tapping task",0.85,Accept,Experimental Usage,Corsi block-tapping task,performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Tower of London Test was used as a measure of Planning Skills,0.85,Accept,Experimental Usage,Tower of London Test,performance test,all ages,No,,,,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"Resting-state 18F-FDG PET/CT brain images were acquired in a GE Discovery 690 (GE Healthcare, Millwalke, EUA) scanner",0.85,Accept,Experimental Usage,GE Discovery 690,biomarker assay,all ages,No,,,,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,We have assessed NF2 clinical phenotype in 142 patients in relation to the UK NF2 Genetic Severity Score to validate its use as a clinical and research tool,0.95,Accept,Experimental Usage,UK NF2 Genetic Severity Score,scale,all ages,Yes,3.0,"3-point classification: tissue mosaicism, classic, severe disease",,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,"Quality of life was assessed using the 8-item NF2 disease-specific quality of life score (0–24), with good internal reliability (Cronbach's α=0.87)",0.9,Accept,Experimental Usage,8-item NF2 disease-specific quality of life score,questionnaire,all ages,Yes,8.0,"0–24 scale, each item rated 0-3",,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,"Hearing grade was assigned based on a score of 1–6, as used within the English NF2 service to indicate suitability for a hearing implant",0.85,Accept,Experimental Usage,hearing grade score,scale,all ages,Yes,6.0,1-6 scale based on Speech Discrimination Score and hearing status,,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,all patients known to the Oxford NF2 centre who met the Manchester NF2 diagnostic criteria and consented to genetic testing were analysed,0.85,Accept,Experimental Usage,Manchester NF2 diagnostic criteria,structured interview,all ages,Yes,,,,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Gait was analyzed using the Noldus Cat-Walk XT system as before,0.9,Accept,Experimental Usage,Noldus Cat-Walk XT system,performance test,all ages,No,,,,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,"EEG signal was recorded from six parieto-occipital channels (PO3, POZ, PO4, O1, OZ and O2) using a 64-channel Neuroscan system",0.8,Accept,Experimental Usage,64-channel Neuroscan system,biomarker assay,pediatric,No,,,,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,"We administered the Portuguese adapted version of the Wechsler Intelligence Scale for Children (WISC-III), in all participants with NF1",0.95,Accept,Experimental Usage,Wechsler Intelligence Scale for Children (WISC-III),performance test,pediatric,No,,,,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,"The stimuli were presented in a CRT monitor (Diamond Digital color monitor, Mitsubishi Electric Australia, Rydalmere, NSW, Australia)",0.75,Accept,Experimental Usage,Diamond Digital color monitor (Mitsubishi Electric Australia),performance test,pediatric,No,,,,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,"patients who fitted Manchester Criteria for NF2 disease (Table S1 ) (Evans et al., 1992 ; Smith et al., 2017 ) were considered to have phenotypic specificity",0.9,Accept,Experimental Usage,Manchester Criteria,scale,all ages,Yes,,,,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,Body fat was measured using the MC‐780MA Tanita Tokyo body composition analyzer. The MC‐780MA body composition analyzer divides the human body into five sections,0.85,Accept,Experimental Usage,MC-780MA Tanita Tokyo body composition analyzer,performance test,pediatric,No,,,,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Maximal isometric strength of three muscle groups involved in prime movements, including grip strength, ankle dorsiflexion, and plantarflexion were tested using hand‐held dynamometry",0.8,Accept,Experimental Usage,Citec hand-held dynamometer,performance test,pediatric,No,,,,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Fine motor endurance was evaluated by the Handwriting Speed Test (Wallen et al., 1996) that gives a raw score in letters per minute",0.9,Accept,Experimental Usage,Handwriting Speed Test,performance test,pediatric,No,,letters per minute,,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"gross motor endurance by the 6MWT, which was completed barefoot on a point‐to‐point, 25‐m long, flat, straight, hard surfaced track",0.95,Accept,Experimental Usage,6-minute-walk test,performance test,pediatric,No,,,,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules",0.95,Accept,Experimental Usage,PedsQL Generic 4.0,questionnaire,caregiver,No,,0–100 scale,,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules",0.95,Accept,Experimental Usage,PedsQL Neuromuscular 3.0,questionnaire,caregiver,Yes,,0–100 scale,,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"The Child Behavior Checklist for ages 6–18 or CBCL/6‐18 (©ASEBA 2020). The CBCL/6‐18 (©ASEBA 2020) consists of 113 questions, scored on a 3‐point Likert scale",0.95,Accept,Experimental Usage,CBCL/6-18,questionnaire,caregiver,No,113.0,Likert 1–3,,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,Participants completed age-appropriate versions of the Wechsler Intelligence Scale,0.85,Accept,Experimental Usage,Wechsler Intelligence Scale,scale,pediatric,No,,,,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,select subtests from A Developmental NEuroPSYchological Assessment (NEPSY-II),0.9,Accept,Experimental Usage,A Developmental NEuroPSYchological Assessment (NEPSY-II),performance test,pediatric,No,,,,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,Pubertal status was assessed by an experienced physician using Tanner staging,0.85,Accept,Experimental Usage,Tanner staging,scale,pediatric,No,,,,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains,0.9,Accept,Experimental Usage,Numeric Rating Scale-11,scale,all ages,No,1.0,0-10 scale,,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains,0.9,Accept,Experimental Usage,Pain Interference Index,questionnaire,all ages,No,6.0,7-point Likert-type scale from 0 (not at all) to 6 (completely),,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,"The self-report NRS-11 has been used in numerous studies, including as a primary outcome measure, to assess pain intensity",0.85,Accept,Experimental Usage,NRS-11,scale,all ages,No,1.0,0-10 scale,,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,The PII is a 6-item questionnaire developed to assess the extent to which pain interferes with six different aspects of daily functioning,0.85,Accept,Experimental Usage,PII,questionnaire,all ages,No,6.0,7-point Likert-type scale from 0 (not at all) to 6 (completely),,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)",0.95,Accept,Development,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),scale,all ages,Yes,,,,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF) and the Pain Interference Index for plexiform neurofibromas (PII-pNF)",0.95,Accept,Development,Pain Interference Index for plexiform neurofibromas (PII-pNF),questionnaire,all ages,Yes,,,,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,"QOL was assessed with the PedsQL 4.0 Generic Core Scales at baseline and prior to cycles 4, 8, 12, 18, and 24. This 23-item questionnaire yields subscale scores...",0.95,Accept,Experimental Usage,PedsQL 4.0 Generic Core Scales,questionnaire,pediatric,No,23.0,0–100 scale,,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)",0.85,Accept,Experimental Usage,Quantikine™ human VEGF immunoassay kit,biomarker assay,pediatric,No,,,,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)",0.85,Accept,Experimental Usage,Quantikine™ human sVEGFR2 immunoassay kit,biomarker assay,pediatric,No,,,,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,Sorafenib plasma concentrations were measured using a validated HPLC/MS/MS method,0.75,Accept,Experimental Usage,HPLC/MS/MS method,biomarker assay,pediatric,No,,,,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,We used the H-score for quantification of FAP immunohistochemistry: 1 × percentage of weak staining) + (2 × percentage of moderate staining) + (3 × percentage of strong staining). The H score ranges from 0 to 300,0.9,Accept,Experimental Usage,H-score,scale,all ages,No,,0-300 scale,,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)",0.95,Accept,Experimental Usage,SF-36,questionnaire,adult,No,36.0,0-100 scale with 8 domains and physical/mental component scores,,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)",0.95,Accept,Experimental Usage,EQ-5D-5L,questionnaire,adult,No,5.0,5 dimensions with 5 response options plus VAS 0-100,,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)",0.95,Accept,Experimental Usage,PROMIS pain interference short form 8a,questionnaire,adult,No,8.0,"T-scores ranging 40.7-77, higher scores indicate worse pain interference",,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),0.95,Accept,Experimental Usage,PedsQL NF1 adult module,questionnaire,adult,Yes,74.0,"5-option Likert scale 0-4, reverse-scored 0-100, higher scores indicate better QoL",,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),0.95,Accept,Experimental Usage,NFTI-QOL,questionnaire,adult,Yes,8.0,"4-point Likert scale 0-3, sum score, higher scores indicate worse QoL",,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,clinicians also rated the disease visibility using the Ablon visibility index,0.9,Accept,Experimental Usage,Ablon visibility index,scale,clinician-rated,Yes,,1-3 scale rating visibility of NF1 manifestations,,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,physicians also completed the House and Brackmann facial nerve scale that rates facial nerve impairments from 1—normal symmetric function to 6—indicating complete paralysis,0.9,Accept,Experimental Usage,House and Brackmann facial nerve scale,scale,clinician-rated,No,6.0,1-6 scale rating facial nerve function,,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements",0.8,Accept,Experimental Usage,Ras activation assay (Millipore),biomarker assay,all ages,No,,,,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements",0.8,Accept,Experimental Usage,cAMP assay (New East Biosciences),biomarker assay,all ages,No,,,,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements",0.8,Accept,Experimental Usage,TUNEL assay (Roche Diagnostics),biomarker assay,all ages,No,,,,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements",0.8,Accept,Experimental Usage,dopamine assay (Rocky Mountain Diagnostics),biomarker assay,all ages,No,,,,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,Morris Water Maze testing for spatial learning and memory was conducted as previously described,0.9,Accept,Experimental Usage,Morris Water Maze,performance test,all ages,No,,,,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,Visual acuity (n=20 mice per group) was assessed using the virtual optokinetic system (VOS) under photopic conditions,0.85,Accept,Experimental Usage,virtual optokinetic system (VOS),performance test,all ages,No,,,,,,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were the primary outcomes...computerized assessment battery (Cogstate) targeting neurocognitive processes,0.9,Accept,Experimental Usage,Cogstate,performance test,all ages,No,,,,,,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,observer-reported functioning (BRIEF) were the primary outcomes...Behavior Rating Inventory of Executive Function; BRIEF,0.9,Accept,Experimental Usage,BRIEF,questionnaire,caregiver,No,,,,,,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,a consistent parent completed a questionnaire of executive functioning (Behavior Rating Inventory of Executive Function; BRIEF),0.85,Accept,Experimental Usage,Behavior Rating Inventory of Executive Function,questionnaire,caregiver,No,,,,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,"A Wood's lamp, which makes CALMs more visible, was used for CALM counting in CALM1, but not in CALM2.",0.8,Accept,Experimental Usage,Wood's lamp,other,all ages,Yes,,,,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,We administered age-appropriate versions of the Wechsler Intelligence Scales to measure global cognitive ability,0.85,Accept,Experimental Usage,Wechsler Intelligence Scales,scale,pediatric,No,,,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"The 22-point (0–21) Basso, Beattie, and Bresnahan (BBB) open-field locomotor test was used to assess hindlimb locomotor function",0.9,Accept,Experimental Usage,BBB open-field locomotor test,scale,all ages,No,22.0,0–21 scale,,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Motor function and motor learning were evaluated by rotarod apparatus,0.8,Accept,Experimental Usage,Rotarod apparatus,performance test,all ages,No,,,,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,The Distress Thermometer (DT) was designed as a brief screening tool to assess for distress in adult cancer patients...the adapted pediatric DT was used in this study for all ages.,0.95,Accept,Experimental Usage,Distress Thermometer (DT),scale,all ages,No,,thermometer scale,,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"The CDI–S (Kovacs, 1992) is a 10-item self-report measure for depression in children, ages 7 to 17 years.",0.9,Accept,Experimental Usage,Children's Depression Inventory (CDI-S),questionnaire,pediatric,No,10.0,self-report measure,,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"The CDI Parent Version (CDI-P) is derived directly from the CDI, is scored identically and has similar psychometric properties...completed by caregivers of all patients, ages 7–21.",0.9,Accept,Experimental Usage,Children's Depression Inventory Parent Version (CDI-P),questionnaire,caregiver,No,,scored identically to CDI,,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"The BSI-18 (Derogatis et al., 2004) is an 18-item self-report measure to screen for psychological distress and psychiatric disorders in individuals in the community or hospital settings.",0.9,Accept,Experimental Usage,Brief Symptom Inventory 18 (BSI-18),questionnaire,adult,No,18.0,T-score with GSI and subscales,,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Medical providers completed a Lansky score for patients 17 years and younger...These scores indicate the disease severity and functional capabilities of the patient,0.85,Accept,Experimental Usage,Lansky Score,scale,pediatric,No,,0–100 scale in increments of 10,,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,a Karnofsky score for patients 18 years and older. These scores indicate the disease severity and functional capabilities of the patient...range from 0–100 in increments of 10,0.85,Accept,Experimental Usage,Karnofsky Score,scale,adult,No,,0–100 scale in increments of 10,,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"Patients, primary caregivers, and the child's primary medical provider rated on a scale of 1–4 how easy or difficult the DT was to complete...The DT Acceptability and Feasibility Scales were developed by the study investigators",0.8,Accept,Development,Distress Thermometer Acceptability and Feasibility Scales,scale,all ages,Yes,,1–4 scale and three point scale,,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,The PlexiQoL is the first disease-specific PRO assessing the ability of adults with NF-1 associated pNFs to meet their basic human needs.,0.95,Accept,Development,PlexiQoL,questionnaire,adult,Yes,18.0,True/Not True response options,,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,"The comparator measure used in the UK was the Nottingham Health Profile (NHP; Hunt et al., 1981)",0.9,Accept,Experimental Usage,Nottingham Health Profile,questionnaire,adult,No,,"0 to 100, where 100 indicates the worst health state",,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,"the Short Form‐36 (SF‐36; Ware & Sherbourne, 1992) was used in the US",0.9,Accept,Experimental Usage,Short Form-36,questionnaire,adult,No,36.0,"0 to 100, with a higher score representing better health",,,,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.,0.85,Accept,Experimental Usage,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,scale,all ages,No,,,,,,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,QOL was assessed using the Impact of Pediatric Illness (IPI) Scale for children 6–18 years of age,0.9,Accept,Experimental Usage,Impact of Pediatric Illness (IPI) Scale,scale,pediatric,No,43.0,0-100 scale,,,,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,STIR MRI of up to three clinically relevant index PN was performed for volumetric analysis,0.8,Accept,Experimental Usage,STIR MRI,biomarker assay,all ages,Yes,,,,,,,,
